Andorra takes a decisive step in its commitment to economic diversification and the attraction of new economic sectors with the project of a pioneering research center dedicated to the development of immunological therapies, promoted by the pharmaceutical holding GRIFOLS. The complex aims to attract scientists and technicians from around the world.
The Pyrenees Immunology Research Center (PYRIC) will be one of the few centers in the World dedicated exclusively to immunology and was born with the vocation of becoming an international reference in the research of developments for treatments for immune system disorders.
The PYRIC will be located in the parish of Ordino through an investment of about 25 million euros and will be fully operative at the end of 2023. The center will create synergies with research centers in other countries and will represent a pole of attraction for highly specialized scientists wishing to relocate to Andorra.
The complex will initially host about 50 scientists, a permanent investigation team and a team of external investigation experts. It will be integrated into the global network of other ten R&D centers by GRIFOLS, which consists in a network of 1,200 scientist and it will be equipped with the latest facilities, systems and technological advances in bioinformatics and data analysis.
Andorra presents the ideal conditions for projects and new initiatives in the field of research and health. GRIFOLS has chosen Andorra for its location, infrastructure, quality of life and the good educational system with an international vocation, as well as for its capacity for global attraction. All of them are very important factors in attracting the best international scientific talent, one of the objectives of PYRIC.